NextStage, an asset management firm, completed the acquisition of a 28.3% stake in Eurobio Scientific, a provider of specialty in vitro diagnostics and life-science solutions, for €36m. “The Covid-19 pandemic has shed new light on infectious disease testing and taken our group into a new dimension on which we want to capitalize in order to reach our new objectives in terms of growth. NextStage AM, which has a strong entrepreneurial-investor culture and an ability to properly assimilate our strategic challenges, seemed to us to be the right partner to become one of the great champions in the In Vitro Diagnostics market," Denis Fortier, Eurobio Scientific Deputy CEO.